Home » Bentley to Present Results of Initial Phase II Intranasal Insulin Study
Bentley to Present Results of Initial Phase II Intranasal Insulin Study
Bentley Pharmaceuticals has recently completed a data analysis of its Phase II clinical trial in Ireland of its proprietary intranasal insulin.
Bentley will report the results in an abstract, titled "Intranasal Insulin Administration in Type I Diabetic Patients Utilizing CPE-215 Technology" at the American Diabetes Association 65th Scientific Sessions, June 10-14.
Bentley previously reported successful completion of the study at the end of 2004. Previous studies of the intranasal insulin development program were published in Diabetes Technology and Therapeutics.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct